Acta Neuropsychiatrica

cambridge.org/neu

Dissecting the association between psychiatric disorders and neurological proteins: a genetic correlation and two-sample bidirectional Mendelian randomization study

Huimei Huang[1], Shiqiang Cheng[2], Chun'e Li[2], Bolun Cheng[2], Li Liu[2], Xuena Yang[2], Peilin Meng[2], Yao Yao[2], Chuyu Pan[2], Jingxi Zhang[2], Huijie Zhang[2], Yujing Chen[2], Zhen Zhang[2], Yan Wen[2], Yumeng Jia[2] and Feng Zhang[2]

[1]Department of Nephrology, Xi'an Children's Hospital, The Affiliated Children's Hospital of Xi'an Jiaotong University, Xi'an, China and [2]Key Laboratory of Trace Elements and Endemic Diseases of National Health and Family Planning Commission; Key Laboratory of Environment and Genes Related to Diseases of Ministry of Education of China; Key Laboratory for Disease Prevention and Control and Health Promotion of Shaanxi Province, School of Public Health, Health Science Center, Xi'an Jiaotong University, Xi'an, China

Original Article

Cite this article: Huang H, Cheng S, Li C, Cheng B, Liu L, Yang X, Meng P, Yao Y, Pan C, Zhang J, Zhang H, Chen Y, Zhang Z, Wen Y, Jia Y, and Zhang F. (2022) Dissecting the association between psychiatric disorders and neurological proteins: a genetic correlation and two-sample bidirectional Mendelian randomization study. *Acta Neuropsychiatrica* **34**:311–317.
doi: 10.1017/neu.2022.10

Received: 12 October 2021
Revised: 22 March 2022
Accepted: 22 March 2022
First published online: 28 March 2022

Key words:
bipolar disorder; schizophrenia; linkage disequilibrium score regression; neurological protein; genetic correlation

Author for correspondence:
Feng Zhang, Email: fzhxjtu@xjtu.edu.cn

Huimei Huang and Shiqiang Cheng contributed equally to this work and share first authorship.

Abstract

Objectives: The role of neurological proteins in the development of bipolar disorder (BD) and schizophrenia (SCZ) remains elusive now. The current study aims to explore the potential genetic correlations of plasma neurological proteins with BD and SCZ. *Methods:* By using the latest genome-wide association study (GWAS) summary data of BD and SCZ (including 41,917 BD cases, 11,260 SCZ cases, and 396,091 controls) derived from the Psychiatric GWAS Consortium website (PGC) and a recently released GWAS of neurological proteins (including 750 individuals), we performed a linkage disequilibrium score regression (LDSC) analysis to detect the potential genetic correlations between the two common psychiatric disorders and each of the 92 neurological proteins. Two-sample Mendelian randomisation (MR) analysis was then applied to assess the bidirectional causal relationship between the neurological proteins identified by LDSC, BD and SCZ. *Results:* LDSC analysis identified one neurological protein, *NEP*, which shows suggestive genetic correlation signals for both BD (coefficient = −0.165, p value = 0.035) and SCZ (coefficient = −0.235, p value = 0.020). However, those association did not remain significant after strict Bonferroni correction. Two sample MR analysis found that there was an association between genetically predicted level of *NEP* protein, BD (odd ratio [OR] = 0.87, p value = 1.61×10^{-6}) and SCZ (OR = 0.90, p value = 4.04×10^{-6}). However, in the opposite direction, there is no genetically predicted association between BD, SCZ, and *NEP* protein level. *Conclusion:* This study provided novel clues for understanding the genetic effects of neurological proteins on BD and SCZ.

Significant outcomes

- Previous genetic studies of bipolar disorder (BD) and schizophrenia (SCZ) have identified multiple shared susceptibility genes, neurometabolites, proteins, and brain morphology changes.
- Linkage disequilibrium score regression identified one neurological protein, *NEP*, which shows suggestive genetic correlation for both BD and SCZ. Two-sample bidirectional Mendelian randomisation analysis suggested an association between genetically predicted levels of *NEP* protein (exposure), BD (outcome) and SCZ (outcome).
- The findings may provide new ideas for future research on the pathogenesis of BD and SCZ and understanding the genetic effects of neurological proteins on BD and SCZ.

Limitations

- Firstly, we observed suggestive genetic correlation between NEP, BD and SCZ. In addition, the instrumental variable used for MR analysis is a trans single nucleotide polymorphisms (SNP) of NEP protein, which may have weaker effect size and less direct effect. Further functional experiment is warranted to confirm our findings and clarify the underlying biological effects of neurological proteins on BD and SCZ.
- Secondly, the GWAS summary statistics all derived from European populations; thus, the results should be applied to other ethnic groups with caution.

Introduction

Bipolar disorder (BD) and Schizophrenia (SCZ) are two common psychiatry disorders shared certain symptoms, such as hallucinations, delusions, and mood symptoms (Yuji *et al.*, 2020). According to the report of The Global Burden of Diseases (GBD), Injuries, and Risk Factors Study 2017, the estimated prevalence around the globe is about 45 million for BD and 19 million for SCZ (James *et al.*, 2018). Both disorders may cause damage to the lives of patients, such as marital instability, low level of education, high social costs, as well as occupational status. With the increasing burden of both disorders (James *et al.*, 2018), its prevention and treatment have become an urgent public health issue.

It has been demonstrated that the combination of both environmental and genetic factors all exert their effect on the development of common psychiatry disorders (Arango *et al.*, 2018). Multiple epidemiological (Lichtenstein *et al.*, 2009) and molecular biological (Ripke *et al.*, 2013) studies have observed shared risk components among BD and SCZ. Recently, the underlying effects of genetic factors in the progression of common psychiatric disorders have been documented in detail. For example, multiple studies focus on the genetic mechanisms of the BD and SCZ have identified multiple shared susceptibility genes, neurometabolites, proteins, and brain morphology changes (Gratacòs *et al.*, 2009). However, the aetiology of the two disorders is still elusive now.

Neurological proteins are a mixture of proteins which involves in the neurobiological processes (such as synaptic function and axon guidance) and neurological-related diseases, as well as potential proteins which play roles in cellular immunology, regulation, and development (Hillary *et al.*, 2019). Previous studies have discovered the relationships between neurological proteins and common psychiatric disorders. For instance, autism spectrum disorders are characterized by defects in axon guidance proteins which will induce a reduction in axonal connections between specific brain regions and an increase in connectivity within specific brain regions (Van Battum *et al.*, 2015). However, there are no systematic studies focus on the role of neurological proteins in common psychiatric disorders.

Linkage disequilibrium score regression (LDSC) has been widely used to evaluate the genetic correlations between different complex traits (Bulik-Sullivan *et al.*, 2015). Mendelian randomisation (MR) analyses enable an assessment of potential causal association between complex traits by using genetic variants as instrumental variables (Smith & Ebrahim, 2005). These two methods are often combined together to explore the association between two traits and the direction of their association. For instance, Kappelmann *et al.* recently applied a combination of the two methods to evaluate the association between inflammation (as indicated by C-reactive protein (CRP) level and IL-6 signalling or activity), BMI (as an index of metabolic dysregulation), and nine specific depressive symptoms (Kappelmann *et al.*, 2021). They reported coheritability between CRP levels and individual depressive symptoms and found that IL-6 signalling is associated with suicidality (Kappelmann *et al.*, 2021).

In this study, we first conducted a LDSC analysis to systematically evaluate the genetic correlations between two common psychiatric disorders and plasma neurological proteins by utilising the latest genome-wide association study (GWAS) summary statistics of neurological proteins and two psychiatric disorders. Two-sample MR analysis was then applied to assess the bidirectional causal relationship between the neurological proteins identified by LDSC and BD, and SCZ.

Materials and methods

GWAS datasets of BD and SCZ

The latest GWAS summary statistics of BD (41,917 cases and 371,549 controls) and SCZ (11,260 cases and 24,542 controls) were derived from the Psychiatric GWAS Consortium (PGC) website (https://www.med.unc.edu/pgc/download-results/) (Mullins *et al.*, 2021, Pardiñas *et al.*, 2018). In short, all study individuals are European populations and diagnosed using research standard diagnoses and expert clinical consensus diagnosis. The genotyping was conducted by multiple platforms, such as Affymetrix SNP 6.0, UK Biobank Axiom Array, Illumina PsychChip, and Illumina 610K chips. Imputation was performed using IMPUTE2 against public reference panels, including the 1000 Genomes Project Phase 2 and Phase 3. Logistic regression model was applied for association analysis. The detail of the experimental design, sample composition, and statistical analysis can be found in the previous studies and supplementary tables 1 and 2 (Mullins *et al.*, 2021, Pardiñas *et al.*, 2018).

GWAS dataset of plasma neurological proteins

The GWAS summary statistics of plasma neurological proteins were downloaded from a recent study (Hillary *et al.*, 2019). Briefly, by using a 92-plex proximity extension assay, Hillary *et al.* carried out a GWAS of the plasma levels of 92 neurological proteins in 750 relatively healthy older adults from the Lothian Birth Cohort 1936 study (Hillary *et al.*, 2019). The proteins assayed constitute the Olink® neurology biomarker panel, including proteins with established evidence in neuropathology and potential proteins which underlie in processing cellular immunology and communication (Hillary *et al.*, 2019). Briefly, the genotyping was conducted by using the Illumina 610-Quadv1 array. The imputation was conducted against the 1000G (phase 1, version 3) reference panel. Linear regression model was applied to evaluate the effect of each genetic variant on the protein residuals using mach2qtl (Hillary *et al.*, 2019). Detailed description of sample composition, quality control, and study design can be found in the previous study (Hillary *et al.*, 2019).

Genetic correlation scanning

Following the standard recommendation from the developers and previous study (Bulik-Sullivan *et al.*, 2015), LDSC software was used for scanning the genetic correlations between BD, SCZ, and each of the 92 neurological proteins. The fundamental of LDSC method is to use the observed $\chi 2$ test statistic to estimate the deviation from the expected value of the SNP directly from the GWAS summary data under the null hypothesis of no correlation (Shi *et al.*, 2016). For a SNP marking more it's neighbours having a higher LD Score, it will be more possible to mark one or more causal loci affecting the trait (Shi *et al.*, 2016). If the detected genetic correlation is statistically significant, then we can be sure that observed correlations cannot be entirely attributable to environmental confounding factors (Lee & Chow, 2017). In addition, Bulik-Sullivan *et al.* have suggested that LDSC can identify genuine pleiotropy from the bias caused by relatedness and population stratification. The LD scores of Europeans were precalculated from the 1000G and used in the current study (Bulik-Sullivan *et al.*, 2015). In this study, we compared the relationships between BD, SCZ, and each of the 92 neurological proteins. The significant association thresholds should be $P < 2.72 \times 10^{-4}$ (0.05/184) after strict

https://doi.org/10.1017/neu.2022.10 Published online by Cambridge University Press

Table 1. Genetic correlations analysis results between the two common psychiatric disorders and plasma neurological protein (p value < 0.05)

Neurological protein	Psychiatric disorders	Coefficients	95% confidence intervals	*P* value	Heritability estimate
NEP	BD	− 0.165	− 0.319 to − 0.011	0.035	0.072
	SCZ	− 0.235	− 0.433 to − 0.037	0.020	0.242

BD, bipolar disorder; SCZ, schizophrenia.

Bonferroni correction. p-Values between 2.72×10^{-4} and 0.05 were considered to be suggestive of significance.

Assessing bidirectional causal relationships between neurological proteins, BD and SCZ

Two-sample MR analysis was then conducted to assess the bidirectional causal relationship between the significant neurological proteins identified by LDSC, BD and SCZ. We first assessed the causal relationship between *NEP* protein (exposure), BD (Stahl *et al.*, 2019) (id: ieu-b-41) (outcome) and SCZ (Consortium, 2014) (id: ieu-b-42) (outcome) by utilising the two-sample MR analysis implemented in "TwoSampleMR" R package. Briefly, a total of 374 SNPs with p-value $< 5 \times 10^{-8}$ of *NEP* GWAS summary statistics were selected for MR analysis and 1 SNP was remained after filtering out SNPs whose distance within 10,000 KB and r2 > 0.001. The ratio of coefficients method, or the Wald method, is the simplest way of estimating the causal effect of the exposure on the outcome by using a single instrument variable (Burgess *et al.*, 2015). Wald ratio method with SNP rs35004449 as the genetic instrument was used in the subsequent MR analysis.

Then the opposite causal effects of BD (exposure) and SCZ (exposure) on *NEP* (outcome) protein were estimated by using the same method. Briefly, a total of 16 SNPs for BD and 81 for SCZ with p-value $< 5 \times 10^{-8}$ were selected for MR analysis, and 9 SNPs for BD and 61 for SCZ were remained, respectively, after filtering out SNPs whose distance within 10,000 KB and r2 > 0.001. We employed the inverse-variance-weighted (IVW) method as primary MR analysis approach in the subsequent MR analysis which estimates causal effects of genetically predicted exposure on outcome through weighted regression of SNP-specific Wald ratios (Burgess *et al.*, 2013).

The causal effect size was reported in beta when the outcome was continuous (i.e. levels of *NEP* protein) and converted to odds ratio (ORs) when the outcome was binary (i.e. BD and SCZ status). An F statistic was estimated to evaluate the strength of these selected instrumental variables for *NEP* protein, BD, and SCZ (Pierce *et al.*, 2011). Generally, an F statistic > 10 was considered as a typical threshold for the selection of strong instrumental variables (Brion *et al.*, 2013).

Results

Genetic correlation between neurological proteins, BD and SCZ

Among the 92 analyzed neurological proteins, we identified *NEP*, which shows suggestive genetic correlation signals for both BD (coefficient = −0.165, p value = 0.035) and SCZ (coefficient = −0.235, p value = 0.020) (Table 1). The overall results of LDSC analysis were summarised in supplementary tables 3 and 4.

Bidirectional causal relationships between neurological proteins, BD and SCZ

All instrumental variables for *NEP* protein, BD, and SCZ were sufficiently informative (F statistic > 10) for MR analyses. For the causal effects of *NEP* protein on BD and SCZ, due to only one instrument variable remains after filtering, we only conducted the two-sample MR analysis by using the Wald ratio method. Based on the Wald ratio method of MR analysis, we found an association between genetically predicted levels of *NEP* protein (exposure), BD (outcome) (OR = 0.87, 95% confidence interval (CI) = 0.82, 0.92, p value = 1.61×10^{-6}) and SCZ (outcome) (OR = 0.90, 95% CI = 0.86, 0.94, p value = 4.04×10^{-6}) (Table 2). However, we did not observe associations between genetically predicted levels of BD, SCZ (exposure), and *NEP* protein (outcome) (Table 2). The overall results of the two-sample bidirectional MR analysis were summarised in Table 2.

Discussion

We conducted a systematic genetic correlation scan between BD, SCZ, and each of the 92 plasma neurological proteins. We identified one plasma neurological protein, *NEP*, showing suggestive genetic correlation evidence with BD and SCZ after strict Bonferroni correction. The two-sample MR analysis also found that *NEP* protein had a causal relationship with BD and SCZ. Those findings may provide novel insights into the pathogenesis and biomarkers studies of BD and SCZ.

It is interesting that *NEP* was identified as a candidate neurological protein for both BD and SCZ by LDSC analysis. Hillary et al. identified a sole independent trans pQTL (rs4687657) for *NEP* annotated to the *ITIH4* gene, as well as two trans genome-wide significant CpG sites (cg11645453 and cg18404041 annotated to *ITIH4* and *ITIH1,* respectively) (Hillary *et al.*, 2019). It has been reported by a previous study that the SNP rs4687657 has been involving with lower methylation levels of cg18404041 (*ITIH4*) and higher DNA methylation levels of cg11645453 (*ITIH1*) (Gaunt *et al.*, 2016). Previous studies have suggested that epigenetic mechanisms such as gene-specific DNA methylation and posttranslational histone modifications may play an important role in the emergence of major psychosis, such as BD and SCZ, and identified some common epigenetic modification patterns among the two diseases (Gürel *et al.*, 2020). For example, Nohesara *et al.* have summarised a great number of DNA methylation alterations in SZ and BD which involved in the regulation of brain functions such as neurogenesis, synaptic plasticity, and neurotransmitter delivery (Nohesara *et al.*, 2011, Pai *et al.*, 2019). Those evidence indicated that the expression of *NEP*, *ITIH1,* and *ITIH4* may be co-regulated, involving the inverse effects between *NEP* and *ITIH1* with *ITIH4* (Sun *et al.*, 2018). A combined GWAS analysis of SCZ and BD have yielded strong evidence for SNPs in the region of *NEK4-ITIH1-ITIH3-ITIH4* associated with the two diseases (Sklar *et al.*, 2011, Witt *et al.*, 2014). Finseth *et al.* observed a new association between

https://doi.org/10.1017/neu.2022.10 Published online by Cambridge University Press

Table 2. The two-sample bidirectional MR analysis results for the association between BD, SCZ, and *NEP* protein

Exposure	Outcome	Number of SNPs	Method	OR or beta (95% CI)	*p*-Value
NEP	BD	1	Wald ratio	0.871 (0.823, 0.921)	1.61×10^{-6}
	SCZ	1	Wald ratio	0.899 (0.859, 0.940)	4.04×10^{-6}
BD	NEP	6	MR Egger	1.631 (−5.961, 9.224)	0.6953
			Weighted median	−0.457 (−1.156, 0.241)	0.1994
			IVW-MRE	−0.645 (−1.637, 0.347)	0.2026
			Simple mode	−0.495 (−1.351, 0.361)	0.3084
			Weighted mode	−0.466 (−1.256, 0.325)	0.3006
SCZ	NEP	54	MR Egger	0.408 (−0.734, 1.55)	0.4873
			Weighted median	0.212 (−0.089, 0.513)	0.1679
			IVW	−0.011 (−0.233, 0.210)	0.9190
			Simple mode	0.466 (−0.161, 1.092)	0.1514
			Weighted mode	0.453 (−0.123, 1.030)	0.1291

MR, Mendelian randomization; BD, bipolar disorder; SCZ, schizophrenia; OR, odd ratio; CI, confidence interval; IVW, Inverse variance weighted; MRE, multiplicative random effects.
The heterogeneity test for BD suggested that *p* Cochran's Q of MR Egger and IVW < 0.05. Therefore, we used IVW method in a MRE model to evaluate the causal effect of BD on *NEP* protein.

ITIH3/4 region and suicide attempt in a group of patients combined with SCZ and BD (Finseth *et al.*, 2014). By using a transmission disequilibrium test in 65 Han Chinese families, the researchers have confirmed a SCZ susceptibility locus on 3p21.1 which encompass the multigenetic region *NEK4-ITIH1-ITIH3-ITIH4* (Li *et al.*, 2020). Given that variants in *NEP* are related to DNA methylation of the susceptibility gene in BD and SCZ, further functional studies are needed to explore its role in the pathogenesis of BD and SCZ.

Two-sample bidirectional MR analysis was conducted to evaluate the genetic correlation direction between *NEP* protein, BD and SCZ identified by LDSC. It is worth noting that the instrumental variable (rs35004449) selected for estimating causal effects of *NEP* protein on BD and SCZ is a 'trans' SNP for *NEP*. Although it is GWAS significant for *NEP* protein and independent of other SNPs, it is not located in the known coding region for *NEP*, but in the *ITIH4* coding region, whereas *NEP* is coded by the *MME* gene. According to the previous study, MR results from analysis of trans SNPS are at particular risk of pleiotropy (e.g. genetic confounding) and typically have weaker effect size and less direct effect, hence are more prone to violate MR assumptions (Porcu *et al.*, 2019). Our results might indicate that perhaps it is not genetically predicted *NEP* itself that influence the risk of BD and SCZ, rather something else related to *ITIH4* that also influences *NEP*. Thus, the findings of this study should be applied with much greater caution. It has been reported that some regulatory SNPs, such as transcription factor binding regions and chromatin interactive regions of *ITIH4,* were involving the genetic mechanism of BD (Qi *et al.*, 2020). Combining with the results of LDSC, *NEP* may be targeted for early diagnosis and treatment of BD and SCZ. However, due to other significant cis-SNPs located within the MME gene is not available, further researches are needed to verify this direct or indirect causal association.

NEP, also known as *MME*, is a neutral endopeptidase that cleaves peptides at the amino side of hydrophobic residues and inactivates several peptide hormones including enkephalins, glucagon, neurotensin, bradykinin, and oxytocin. We observed suggestive genetic correlation and causal relationship between *NEP* protein with both BD and SCZ, which is consistent with previous studies that BD and SCZ shared common genetic mechanism (Ripke *et al.*, 2013, Lichtenstein *et al.*, 2009). Neurotensin is a neuropeptide that has been implicated in the biology of SCZ by modulating dopaminergic and other neurotransmitter systems (Perreault *et al.*, 2010, Wolf *et al.*, 1995). It has been reported that neurotensin receptor agonists have the capacity to be used as novel therapeutic strategy for the treatment of SCZ (Boules *et al.*, 2007).

The advantages of current study are that because of using GWAS summary statistics, the findings should not be easily affected by environmental confounding factors. In addition, some limitations of our study should be noted. First, the main objective of current study is to detect the genetic correlations between plasma neurological proteins, BD and SCZ, and to discover novel candidate neurological proteins related to BD and SCZ. Further functional experimental researchers are warranted to validate the results and clarify the potential genetic mechanisms of NEP protein in the development of BD and SCZ. Secondly, the GWAS summary statistics used in the current study are all from European populations; thus, the study results should be applied to other ethnic groups with caution. In addition, the sample size for the GWAS used for neurological proteins is extremely small and so highly likely to be underpowered to detect all but the genetic variants with the strongest signals, it may at present preclude an informative LDSC and MR study examining genetic similarity between neurological proteins and mental disorders. Thirdly, after strict multiple testing correction, the significant threshold should be $P < 2.72 \times 10^{-4}$ (0.05/184). Unfortunately, according to our results, the *NEP* protein identified in this study shows suggestive association with the BD and SCZ. So, our results should be interpreted carefully.

In summary, by applying the widely used genetic approach, we conducted a combination of LDSC and two-sample bidirectional MR analysis to explore the genetic correlations and causal associations between neurological proteins, BD and SCZ. Our study identified one candidate neurological proteins showing suggestive association signal and potential causal relationship with both BD and SCZ. The findings may provide new ideas for future research on the pathogenesis of BD and SCZ and understanding the genetic effects of neurological proteins on BD and SCZ.

https://doi.org/10.1017/neu.2022.10 Published online by Cambridge University Press

Supplementary material. For supplementary material accompanying this paper visit https://doi.org/10.1017/neu.2022.10

Data availability statement. All of the data analyzed in this study were downloaded from the Internet.

Acknowledgements. None.

Author contributions. HM, SC and FZ conceived and designed the study and wrote the manuscript; HM, SC and FZ collected the data and carried out the statistical analyses; CL, BC, LL, XL, PM, YY, CP, JZ, HZ, YC, ZZ, YW and YJ made preparations for the manuscript at first.

Financial support. This study is supported by the National Natural Scientific Foundation of China (81922059) and the Fundamental Research Funds for the Central Universities.

Conflict of interest. None.

Ethical statement. There is no ethical statement here because of all the data downloaded from the Internet.

References

Arango C, Diazcaneja CM, Mcgorry PD, Rapoport JL, Sommer IEC, Vorstman J, Mcdaid D, Marin O, Serranodrozdowskyj E, Freedman R (2018) Preventive strategies for mental health. *The Lancet Psychiatry* **5**(7), 591–604.

Boules M, Shaw A, Fredrickson P and Richelson E (2007) Neurotensin agonists: potential in the treatment of schizophrenia. *CNS Drugs* **21**(1), 13–23.

Brion MJ, Shakhbazov K and Visscher PM (2013) Calculating statistical power in Mendelian randomization studies. *International Journal of Epidemiology* **42**(5), 1497–1501.

Bulik-Sullivan B, Finucane HK, Anttila V, Gusev A, Day FR, ReproGen Consortium; Psychiatric Genomics Consortium; Genetic Consortium for Anorexia Nervosa of the Wellcome Trust Case Control Consortium 3, Duncan L, Perry JRB, Patterson N, Robinson E, Daly MJ, Price AL and Neale BM (2015) An atlas of genetic correlations across human diseases and traits. *Nature Genetics* **47**(11), 1236–1241.

Burgess S, Butterworth A and Thompson SG (2013) Mendelian randomization analysis with multiple genetic variants using summarized data. *Genetic Epidemiology* **37**(7), 658–665.

Burgess S, Small DS and Thompson SG (2015) A review of instrumental variable estimators for Mendelian randomization. *Statistical Methods in Medical Research* **26**(5), 2333–2355.

Consortium SWGOTPG (2014) Biological insights from 108 schizophrenia-associated genetic loci. *Nature* **511**(7510), 421–427.

Finseth PI, Sønderby IE, Djurovic S, Agartz I, Malt UF, Melle I, Morken G, Andreassen OA, Vaaler AE, Tesli M (2014) Association analysis between suicidal behaviour and candidate genes of bipolar disorder and schizophrenia. *Journal of Affective Disorders* **163**, 110–114.

Gaunt TR, Shihab HA, Hemani G, Min JL, Woodward G, Lyttleton O, Zheng J, Duggirala A, Mcardle WL, Ho K, Ring SM, Evans DM, Davey Smith G, Relton CL (2016) Systematic identification of genetic influences on methylation across the human life course. *Genome Biology* **17**, 61.

Gratacòs M, Costas J, de Cid R, Bayés M, González JR, Baca-García E, de Diego Y, Fernández-Aranda F, Fernández-Piqueras J, Guitart M, Martín-Santos R, Martorell L, Menchón JM, Roca M, Sáiz-Ruiz J, Sanjuán J, Torrens M, Urretavizcaya M, Valero J, Vilella E, Estivill X and Carracedo Á (2009) Identification of new putative susceptibility genes for several psychiatric disorders by association analysis of regulatory and non-synonymous SNPs of 306 genes involved in neurotransmission and neurodevelopment. *American Journal of Medical Genetics. Part B* **150B**(6), 808–816.

Gürel Ç., Kuşçu GC, Yavaşoğlu A and Biray Avcı Ç. (2020) The clues in solving the mystery of major psychosis: the epigenetic basis of schizophrenia and bipolar disorder. *Neuroscience & Biobehavioral Reviews* **113**(519), 51–61.

Hillary RF, Mccartney DL, Harris SE, Stevenson AJ, Seeboth A, Zhang Q, Liewald DC, Evans KL, Ritchie CW, Tucker-Drob EM, Wray NR, Mcrae AF, Visscher PM, Deary IJ, Marioni RE (2019) Genome and epigenome wide studies of neurological protein biomarkers in the Lothian Birth Cohort 1936. *Nature Communications* **10**, 3160.

James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, Abbastabar H, Abd-Allah F, Abdela J, Abdelalim A, Abdollahpour I, Abdulkader RS, Abebe Z, Abera SF, Abil OZ, Abraha HN, Abu-Raddad LJ, Abu-Rmeileh NME, Accrombessi MMK, Acharya D, Acharya P, Ackerman IN, Adamu AA, Adebayo OM, Adekanmbi V, Adetokunboh OO, Adib MG, Adsuar JC, Afanvi KA, Afarideh M, Afshin A, Agarwal G, Agesa KM, Aggarwal R, Aghayan SA, Agrawal S, Ahmadi A, Ahmadi M, Ahmadieh H, Ahmed MB, Aichour AN, Aichour I, Aichour MTE, Akinyemiju T, Akseer N, Al-Aly Z, Al-Eyadhy A, Al-Mekhlafi HM, Al-Raddadi RM, Alahdab F, Alam K, Alam T, Alashi A, Alavian SM, Alene KA, Alijanzadeh M, Alizadeh-Navaei R, Aljunid SM, Alkerwi AA, Alla F, Allebeck P, Alouani MML, Altirkawi K, Alvis-Guzman N, Amare AT, Aminde LN, Ammar W, Amoako YA, Anber NH, Andrei CL, Androudi S, Animut MD, Anjomshoa M, Ansha MG, Antonio CAT, Anwari P, Arabloo J, Arauz A, Aremu O, Ariani F, Armoon B, Ärnlöv J, Arora A, Artaman A, Aryal KK, Asayesh H, Asghar RJ, Ataro Z, Atre SR, Ausloos M, Avila-Burgos L, Avokpaho EFGA, Awasthi A, Ayala Quintanilla BP, Ayer R, Azzopardi PS, Babazadeh A, Badali H, Badawi A, Bali AG, *et al.* (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *The Lancet* **392**(10159), 1789–1858.

Kappelmann N, Arloth J, Georgakis MK, Czamara D, Rost N, Ligthart S, Khandaker GM and Binder EB (2021) Dissecting the association between inflammation, metabolic dysregulation, and specific depressive symptoms: a genetic correlation and 2-sample Mendelian randomization study. *JAMA Psychiatry* **78**(2), 161–170.

Lee JJ and Chow CCJB (2017) LD Score regression as an estimator of confounding and genetic correlations in genome-wide association studies. *bioRxiv*, 234815.

Li M, Shen L, Chen L, Huai C, Huang H, Wu X, Yang C, Ma J, Zhou W, Du H, Fan L, He L, Wan C, Qin S (2020) Novel genetic susceptibility loci identified by family based whole exome sequencing in Han Chinese schizophrenia patients. *Translational Psychiatry* **10**(1), 5.

Lichtenstein P, Yip BH, Björk C, Pawitan Y, Cannon TD, Sullivan PF and Hultman CM (2009) Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. *The Lancet* **373**(9659), 234–239.

Mullins N, Forstner AJ, O'connell KS, Coombes B, Coleman JRI, Qiao Z, Als TD, Bigdeli TB, Børte S, Bryois J, Charney AW, Drange OK, Gandal MJ, Hagenaars SP, Ikeda M, Kamitaki N, Kim M, Krebs K, Panagiotaropoulou G, Schilder BM, Sloofman LG, Steinberg S, Trubetskoy V, Winsvold BS, Won HH, Abramova L, Adorjan K, Agerbo E, Al Eissa M, Albani D, Alliey-Rodriguez N, Anjorin A, Antilla V, Antoniou A, Awasthi S, Baek JH, Bækvad-Hansen M, Bass N, Bauer M, Beins EC, Bergen SE, Birner A, BØCKER Pedersen C, Bøen E, Boks MP, Bosch R, Brum M, Brumpton BM, Brunkhorst-Kanaan N, Budde M, Bybjerg-Grauholm J, Byerley W, Cairns M, Casas M, Cervantes P, Clarke TK, Cruceanu C, Cuellar-Barboza A, Cunningham J, Curtis D, Czerski PM, Dale AM, Dalkner N, David FS, Degenhardt F, Djurovic S, Dobbyn AL, Douzenis A, Elvsåshagen T, Escott-Price V, Ferrier IN, Fiorentino A, Foroud TM, Forty L, Frank J, Frei O, Freimer NB, Frisén L, Gade K, Garnham J, Gelernter J, Giørtz Pedersen M, Gizer IR, Gordon SD, Gordon-Smith K, Greenwood TA, Grove J, Guzman-Parra J, Ha K, Haraldsson M, Hautzinger M, Heilbronner U, Hellgren D, Herms S, Hoffmann P, Holmans PA, Huckins L, Jamain S, Johnson JS, Kalman JL, *et al.* (2021) Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. *Nature Genetics* **53**, 817–829.

Nohesara S, Ghadirivasfi M, Mostafavi S, Eskandari M-R, Ahmadkhaniha H, Thiagalingam S and Abdolmaleky HM (2011) DNA hypomethylation of MB-COMT promoter in the DNA derived from saliva in schizophrenia and bipolar disorder. *Journal of Psychiatric Research* **45**(11), 1432–1438.

Pai S, P. LI, Killinger B, Marshall L, Jia P, Liao J, Petronis A, Szabó PE and Labrie V (2019) Differential methylation of enhancer at IGF2 is associated with abnormal dopamine synthesis in major psychosis. *Nature Communications* **10**, 2046.

Pardiñas AF, Holmans P, Pocklington AJ, Escott-Price V, Ripke S, Carrera N, Legge SE, Bishop S, Cameron D, Hamshere ML, Han J, Hubbard L, Lynham A, Mantripragada K, Rees E, Maccabe JH, Mccarroll SA, Baune BT, Breen G, Byrne EM, Dannlowski U, Eley TC, Hayward C, Martin NG, Mcintosh AM, Plomin R, Porteous DJ, Wray NR, Caballero A, Geschwind DH, Huckins LM, Ruderfer DM, Santiago E, Sklar P, Stahl EA, Won H, Agerbo E, Als TD, Andreassen OA, Bækvad-Hansen M, Mortensen PB, Pedersen CB, Børglum AD, Bybjerg-Grauholm J, Djurovic S, Durmishi N, Pedersen MG, Golimbet V, Grove J, Hougaard DM, Mattheisen M, Molden E, Mors O, Nordentoft M, Pejovic-Milovancevic M, Sigurdsson E, Silagadze T, Hansen CS, Stefansson K, Stefansson H, Steinberg S, Tosato S, Werge T, Harold D, Sims R, Gerrish A, Chapman J, Escott-Price V, Abraham R, Hollingworth P, Pahwa J, Denning N, Thomas C, Taylor S, Powell J, Proitsi P, Lupton M, Lovestone S, Passmore P, Craig D, Mcguinness B, Johnston J, Todd S, Maier W, Jessen F, Heun R, Schurmann B, Ramirez Z, Becker T, Herold C, Lacour A, Drichel D, Nothen M, Goate A, Cruchaga C, Nowotny P, Morris JC, Mayo K, Holmans P, O'donovan M, *et al.* (2018) Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. *Nature Genetics* **50**, 381–389.

Perreault ML, Hasbi A, Alijaniaram M, Fan T, Varghese G, Fletcher PJ, Seeman P, O'dowd BF and George SR (2010) The dopamine D1-D2 receptor heteromer localizes in dynorphin/enkephalin neurons: increased high affinity state following amphetamine and in schizophrenia. *Journal of Biological Chemistry* **285**(47), 36625–36634.

Pierce BL, Ahsan H and Vanderweele TJ (2011) Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. *International Journal of Epidemiology* **40**(3), 740–752.

Porcu E, Rüeger S, Lepik K, Agbessi M, Ahsan H, Alves I, Andiappan A, Arindrarto W, Awadalla P, Battle A, Beutner F, Jan Bonder M, Boomsma D, Christiansen M, Claringbould A, Deelen P, Esko T, Favé M-J, Franke L, Frayling T, Gharib S A, Gibson G, Heijmans B T, Hemani G, Jansen R, Kähönen M, Kalnapenkis A, Kasela S, Kettunen J, Kim Y, Kirsten H, Kovacs P, Krohn K, Kronberg-Guzman J, Kukushkina V, Lee B, Lehtimäki T, Loeffler M, Marigorta U M, Mei H, Milani L, Montgomery G W, Müller-Nurasyid M, Nauck M, Nivard M, Penninx B, Perola M, Pervjakova N, Pierce B L, Powell J, Prokisch H, Psaty B M, Raitakari O T, Ripatti S, Rotzschke O, Saha A, Scholz M, Schramm K, Seppälä I, Slagboom E P, Stehouwer C D A, Stumvoll M, Sullivan P, 't Hoen P A C, Teumer A, Thiery J, Tong L, Tönjes A, van Dongen J, van Iterson M, van Meurs J, Veldink J H, Verlouw J, Visscher P M, Völker U, Võsa U, Westra H-J, Wijmenga C, Yaghootkar H, Yang J, Zeng B, Zhang F, Arindrarto W, Beekman M, Boomsma D I, Bot J, Deelen J, Deelen P, Franke L, Heijmans B T, 't Hoen P A C, Hofman B A, Hottenga J J, Isaacs A, Bonder M J, Jhamai P M, Jansen R, Kielbasa S M, Lakenberg N, Luijk R, *et al.* (2019) Mendelian randomization integrating GWAS and eQTL data reveals genetic determinants of complex and clinical traits. *Nature Communications* **10**, 3300.

Qi X, Wen Y, P. LI, Liang C, Cheng B, Ma M, Cheng S, Zhang L, Liu L, Kafle OP, Zhang F (2020) An integrative analysis of genome-wide association study and regulatory SNP annotation datasets identified candidate genes for bipolar disorder. *International Journal of Bipolar Disorders* **8**(1), 6.

Ripke S, O'dushlaine C, Chambert K, Moran JL, Kähler AK, Akterin S, Bergen SE, Collins AL, Crowley JJ, Fromer M, Kim Y, Lee SH, Magnusson PK, Sanchez N, Stahl EA, Williams S, Wray NR, Xia K, Bettella F, Borglum AD, Bulik-Sullivan BK, Cormican P, Craddock N, De Leeuw C, Durmishi N, Gill M, Golimbet V, Hamshere ML, Holmans P, Hougaard DM, Kendler KS, Lin K, Morris DW, Mors O, Mortensen PB, Neale BM, O'neill FA, Owen MJ, Milovancevic MP, Posthuma D, Powell J, Richards AL, Riley BP, Ruderfer D, Rujescu D, Sigurdsson E, Silagadze T, Smit AB, Stefansson H, Steinberg S, Suvisaari J, Tosato S, Verhage M, Walters JT, Levinson DF, Gejman PV, Kendler KS, Laurent C, Mowry BJ, O'donovan MC, Owen MJ, Pulver AE, Riley BP, Schwab SG, Wildenauer DB, Dudbridge F, Alexander M, Holmans P, Shi J, Albus M, Campion D, Cohen D, Dikeos D, Duan J, Eichhammer P, Godard S, Lerer FM, Hansen M, Liang KY, Maier W, Mallet J, Nertney DA, Nestadt G, Nestadt G, Norton N, O'neill FA, Papadimitriou GN, Ribble R, Sanders AR, Silverman JM, Walsh D, Williams NM, Wormley B, Arranz MJ, Bakker S, Bender S, Bramon E, Collier D, Crespo-Facorro B, Hall J, Iyegbe C, *et al.* (2013) Genome-wide association analysis identifies 13 new risk loci for schizophrenia. *Nature Genetics* **45**, 1150–1159.

Shi H, Kichaev G and Pasaniuc B (2016) Contrasting the genetic architecture of 30 complex traits from summary association data. *American Journal of Human Genetics* **99**, 139–153.

Sklar P, Ripke S, Scott LJ, Andreassen OA, Cichon S, Craddock N, Edenberg HJ, Nurnberger JI, Rietschel M, Blackwood D, Corvin A, Flickinger M, Guan W, Mattingsdal M, Mcquillin A, Kwan P, Wienker TF, Daly M, Dudbridge F, Holmans PA, Lin D, Burmeister M, Greenwood TA, Hamshere ML, Muglia P, Smith EN, Zandi PP, Nievergelt CM, Mckinney R, Shilling PD, Schork NJ, Bloss CS, Foroud T, Koller DL, Gershon ES, Liu C, Badner JA, Scheftner WA, Lawson WB, Nwulia EA, Hipolito M, Coryell W, Rice J, Byerley W, Mcmahon FJ, Schulze TG, Berrettini W, Lohoff FW, Potash JB, Mahon PB, Mcinnis MG, Zöllner S, Zhang P, Craig DW, Szelinger S, Barrett TB, Breuer R, Meier S, Strohmaier J, Witt SH, Tozzi F, Farmer A, Mcguffin P, Strauss J, W. XU, Kennedy JL, Vincent JB, Matthews K, Day R, Ferreira MA, O'dushlaine C, Perlis R, Raychaudhuri S, Ruderfer D, Lee PH, Smoller JW, Li J, Absher D, Bunney WE, Barchas JD, Schatzberg AF, Jones EG, Meng F, Thompson RC, Watson SJ, Myers RM, Akil H, Boehnke M, Chambert K, Moran J, Scolnick E, Djurovic S, Melle I, Morken G, Gill M, Morris D, Quinn E, Mühleisen TW, Degenhardt FA, Mattheisen M, *et al.* (2011) Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. *Nature Genetics* **43**, 977–983.

Smith GD and Ebrahim S (2005) What can mendelian randomisation tell us about modifiable behavioural and environmental exposures? *BMJ* **330**(7499), 1076–1079.

Stahl EA, Breen G, Forstner AJ, Mcquillin A, Ripke S, Trubetskoy V, Mattheisen M, Wang Y, Coleman JRI, Gaspar HA, de Leeuw CA, Steinberg S, Pavlides JMW, Trzaskowski M, Byrne EM, Pers TH, Holmans PA, Richards AL, Abbott L, Agerbo E, Akil H, Albani D, Alliey-Rodriguez N, T.D. ALS, Anjorin A, Antilla V, Awasthi S, Badner JA, Bækvad-Hansen M, Barchas JD, Bass N, Bauer M, Belliveau R, Bergen SE, Pedersen CB, Bøen E, Boks MP, Boocock J, Budde M, Bunney W, Burmeister M, Bybjerg-Grauholm J, Byerley W, Casas M, Cerrato F, Cervantes P, Chambert K, Charney AW, Chen D, Churchhouse C, Clarke T-K, Coryell W, Craig DW, Cruceanu C, Curtis D, Czerski PM, Dale AM, de Jong S, Degenhardt F, Del-Favero J, Depaulo JR, Djurovic S, Dobbyn AL, Dumont A, Elvsåshagen T, Escott-Price V, Fan CC, Fischer SB, Flickinger M, Foroud TM, Forty L, Frank J, Fraser C, Freimer NB, Frisén L, Gade K, Gage D, Garnham J, Giambartolomei C, Pedersen MG, Goldstein J, Gordon SD, Gordon-Smith K, Green EK, Green MJ, Greenwood TA, Grove J, Guan W, Guzman-Parra J, Hamshere ML, Hautzinger M, Heilbronner U, Herms S, Hipolito M, Hoffmann P, Holland D, Huckins L, Jamain S, Johnson JS, Juréus A, *et al.* (2019) Genome-wide association study identifies 30 loci associated with bipolar disorder. *Nature Genetics* **51**, 793–803.

Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, Burgess S, Jiang T, Paige E, Surendran P, Oliver-Williams C, Kamat MA, Prins BP, Wilcox SK, Zimmerman ES, Chi A, Bansal N, Spain SL, Wood AM, Morrell NW, Bradley JR, Janjic N, Roberts DJ, Ouwehand WH, Todd JA, Soranzo N, Suhre K, Paul DS, Fox CS, Plenge RM, Danesh J, Runz H and Butterworth AS (2018) Genomic atlas of the human plasma proteome. *Nature* **558**(7708), 73–79.

https://doi.org/10.1017/neu.2022.10 Published online by Cambridge University Press

van Battum EY, Brignani S and Pasterkamp RJ (2015) Axon guidance proteins in neurological disorders. *The Lancet Neurology* **14**(5), 532–546.

Witt SH, Juraeva D, Sticht C, Strohmaier J, Meier S, Treutlein J, Dukal H, Frank J, Lang M, Deuschle M, Schulze TG, Degenhardt F, Mattheisen M, Brors B, Cichon S, Nöthen MM, Witt CC, Rietschel M (2014) Investigation of manic and euthymic episodes identifies state- and trait-specific gene expression and STAB1 as a new candidate gene for bipolar disorder. *Translational Psychiatry* **4**(8), e426.

Wolf SS, Hyde TM, Saunders RC, Herman MM, Weinberger DR and Kleinman JE (1995) Autoradiographic characterization of neurotensin receptors in the entorhinal cortex of schizophrenic patients and control subjects. *Journal of Neural Transmission* **102**(1), 55–65.

Yuji Y, Madoka M, Kazuki I and Tomiki S (2020) Specificity and continuity of schizophrenia and bipolar disorder: relation to biomarkers. *Current Pharmaceutical Design* **26**(2), 191–200.

https://doi.org/10.1017/neu.2022.10 Published online by Cambridge University Press